Concomitant Treatment with Etanercept and Tacrolimus Synergistically Attenuates Arthritis Progression via Inhibition of Matrix Metalloproteinase-3 Production and Osteoclastogenesis in Human TNF-α Transgenic Mice

Figure 5

Etanercept (ETN) and tacrolimus (TAC) inhibit the differentiation of RAW 264.7 cells into TRAP-positive multinuclear cells. RAW 264.7 cells were cultured in the presence of 10 ng/mL RANKL for 2 days and then stimulated with 10 ng/mL RANKL and 10 ng/mL recombinant human TNF-α in the presence or absence of the drugs for 3 days and stained for TRAP. (a) Representative images of each drug treatment group are shown. . (b) Results are shown as the number of TRAP-positive multinuclear cells and the (). compared with 15 ng/mL ETN single-drug treatment; compared with 150 ng/mL ETN single-drug treatment; compared with the no-drug treatment group (Dunnett’s multiple comparison test). (c) The results of single and concomitant drug treatments on cell viability under the in vitro osteoclastogenesis assay. Results are shown as absorbance at 450 nm and the (). compared with the nontreatment group (Aspin-Welch’s -test). and compared with the no-drug treatment group (Dunnett’s multiple comparison test).

(a)

(b)

(c)